March 29, 2018 / 5:06 PM / 7 months ago

Pfizer's rare disease drug succeeds in late-stage study

March 29 (Reuters) - Pfizer Inc said on Thursday its drug for a rare and fatal disease associated with progressive heart failure met the main goal in a late-stage study.

The company said the drug, tafamidis, showed statistically significant reduction in deaths and frequency of cardiovascular-related hospitalizations compared to a placebo at 30 months. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below